GMED.......GenoMed Offers Trial for Influenza and Avian Influenza

[setravis]

Nice move on the news......
Above the 50-day MA.....Breaking through the 200-day MA.
Technicals
Most Actives
Percentage Gainer

Last Price Quote is:
36.57%above 13-day EMA
36.03%above 50-day EMA
RS Rating: 77 

Market Cap (M): $36.45

[setravis]

Profile Get Profile for: 


GenoMed Inc.
9666 Olive Boulevard
Suite 310
St Louis, MO 63132
Phone: 314-983-9933
Web Site: http://www.genomedics.com

DETAILS   
Index Membership: N/A
Sector: 
Industry: 
Full Time Employees: 6


BUSINESS SUMMARY   
GenoMed, Inc., a development stage medical genomics company, intends to translate knowledge of disease genes into the development of new treatments, better use of existing therapies, and creation of accurate gene-based tests for known diseases. The company's customers include pharmaceutical companies, other biotechnology companies, and diagnostic laboratories. It was formed as e-Kids Network, Inc. in January 2001 and changed its name to GenoMed, Inc. in October 2001. GenoMed is based in St. Louis, Missouri.

[setravis]

Press Release Source: GenoMed


GenoMed Offers Trial for Influenza and Avian Influenza
Thursday October 13, 9:30 am ET


ST. LOUIS, Oct. 13 /PRNewswire-FirstCall/ -- GenoMed (Pink Sheets: GMED - News), a Next Generation Disease Management company whose business is public health, announced today that it has begun Internet-based clinical trials for influenza and avian influenza, since the same treatment approach is expected to work for both kinds of virus.


There is currently no reliable vaccine or treatment for avian influenza. There are antiviral drugs and a vaccine for regular influenza, but they're far from perfect. The yearly influenza vaccine was recently reported to work in only a third of patients.

GenoMed's treatment has been 80% effective in a limited number of patients with West Nile virus encephalitis since 2003. The company is now ready to test it in viral pneumonias.

Any one interested in signing up for GenoMed's clinical trial just needs to go to GenoMed's website ( http://www.genomed.com ), and then click on "Company News" followed by "Investor Relations/Press Releases" followed by "Presentations" (in the upper right-hand corner). The trial documents are self-explanatory.

About GenoMed

GenoMed's broad-spectrum anti-viral approach was specifically mentioned in BioShield II, recently introduced in the US Senate (see Section 2151 of Senate bill S. 975).

Safe Harbor Statement

This press release contains forward-looking statements, including those statements pertaining to GenoMed, Inc.'s (the Company's) finances and treatments. The words or phrases "ought to," "should," "could," "may," or similar expressions are intended to identify "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from those projected in the forward looking statements as a result of a number of risks and uncertainties, including but not limited to our research and development being subject to scientific, economic, regulatory, governmental, and technological factors. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. Unless otherwise required by applicable law, we specifically disclaim any obligation to update any forward- looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.




--------------------------------------------------------------------------------
Source: GenoMed

[setravis]

Catching on fire.......
+60.00%.........Volume now @ 3,114,113

[tommyt]

Setravis,
Once again, good find. I have an order in of 50k @ .06, and I'm prepared if it falls 50%. Upside appears worth it.

Thanks